The drug and the review Plerixafor was licensed in the UK in August 2009 to be used in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. The recommended dose of plerixafor is 0.24mg/kg body weight per day (to a max...

Reversed-phase high-performance liquid chromatography (RP-HPLC) of therapeutic proteins continues to play a significant role in product characterization. This study focuses on two key aspects of HPLC method development, namely the selection of organic modifier and the gradient shape. Separation of granulocyte colony-stimulating factor variants is being used as a case study to illustrate these c...

Aim: We aimed to analyse the long-term effects of biosimilar bids NEAK regarding GCSF and EPO drugs. Data Methods: Our analysis is based on data derived from nationwide pharmaceutical database NEAK. The treatment days reimbursement figures 12 months periods has been compared, 01.07.2011-30.06.2014. 01.07.2017.-30.06.2019. Results: In preceding price competition bid products 13974 patients recei...